Matinas BioPharma to Participate in Two Upcoming Virtual Investor Conferences
Matinas BioPharma Holdings (MTNB) announced that CEO Jerome D. Jabbour will present at two virtual investor conferences. The first is the LD Micro Virtual Conference on September 2, 2020, at 12:00 p.m. ET, and the second is the HC Wainwright 22nd Annual Global Investment Conference on September 16, 2020, at 12:30 p.m. ET. Both presentations will have live webcasts available on the company’s investor relations page, with replays accessible for 90 days. Matinas is focused on developing MAT9001 for cardiovascular conditions and MAT2203 for invasive fungal infections.
- None.
- None.
BEDMINSTER, N.J., Aug. 26, 2020 (GLOBE NEWSWIRE) -- Matinas BioPharma Holdings, Inc. (NYSE AMER: MTNB), today announced that Jerome D. Jabbour, Chief Executive Officer, has been invited to present a Company overview and host one-on-one meetings during two upcoming virtual investor conferences.
Details are as follows:
| Event | LD Micro Virtual Conference |
| Date | September 2, 2020 |
| Time | 12:00 p.m. ET |
| Event | HC Wainwright 22nd Annual Global Investment Conference |
| Date | September 16, 2020 |
| Time | 12:30 p.m. ET |
Investors interested in arranging a virtual meeting with the Company's management during either conference should contact the respective conference coordinator.
A live webcast of both presentations will be available on the IR Calendar page of the Investors section of the Company’s website (www.matinasbiopharma.com). A webcast replay will be accessible for 90 days following each live presentation.
About Matinas BioPharma
Matinas BioPharma is a clinical-stage biopharmaceutical company focused on development of its lead product candidate, MAT9001, for the treatment of cardiovascular and metabolic conditions. MAT9001 is a prescription-only omega-3 fatty acid-based composition, comprised primarily of EPA and DPA, under development for hypertriglyceridemia, that was specifically designed to overcome the shortcomings seen from other agents in the omega-3 class. Company leadership has a deep history and knowledge of cardiovascular drug development and is supported by a world-class team of scientific advisors.
In addition, the Company is developing MAT2203, an oral, encochleated formulation of amphotericin B, to treat serious invasive fungal infections. The drug is based on the Company’s proprietary lipid nano-crystal (LNC) platform delivery technology, which can help solve complex challenges relating to the safe and effective delivery of potent medicines, potentially making them more targeted, less toxic and orally bioavailable.
Forward-Looking Statements
This release contains "forward-looking statements" within the meaning of the Private Securities Litigation Reform Act of 1995, including those relating to the Company's anticipated capital and liquidity needs, strategic focus and the future development of its product candidates, including MAT9001 and MAT2203, the anticipated timing of regulatory submissions, the anticipated timing of clinical studies, the anticipated timing of regulatory interactions, the Company’s ability to identify and pursue development and partnership opportunities for its products or platform delivery technology on favorable terms, if at all, and the ability to obtain required regulatory approval and other statements that are predictive in nature, that depend upon or refer to future events or conditions. All statements other than statements of historical fact are statements that could be forward-looking statements. Forward-looking statements include words such as "expects," "anticipates," "intends," "plans," "could," "believes," "estimates" and similar expressions. These statements involve known and unknown risks, uncertainties and other factors which may cause actual results to be materially different from any future results expressed or implied by the forward-looking statements. Forward-looking statements are subject to a number of risks and uncertainties, including, but not limited to, our ability to obtain additional capital to meet our liquidity needs on acceptable terms, or at all, including the additional capital which will be necessary to complete the clinical trials of our product candidates; our ability to successfully complete research and further development and commercialization of our product candidates; the uncertainties inherent in clinical testing; the timing, cost and uncertainty of obtaining regulatory approvals; our ability to protect the Company's intellectual property; the loss of any executive officers or key personnel or consultants; competition; changes in the regulatory landscape or the imposition of regulations that affect the Company's products; and the other factors listed under "Risk Factors" in our filings with the SEC, including Forms 10-K, 10-Q and 8-K. Investors are cautioned not to place undue reliance on such forward-looking statements, which speak only as of the date of this release. Except as may be required by law, the Company does not undertake any obligation to release publicly any revisions to such forward-looking statements to reflect events or circumstances after the date hereof or to reflect the occurrence of unanticipated events. Matinas BioPharma's product candidates are all in a development stage and are not available for sale or use.
Investor and Media Contacts
Peter Vozzo
Westwicke
443-213-0505
peter.vozzo@westwicke.com
Ian Cooney
Director – Investor Relations & Corporate Development
Matinas Biopharma, Inc.
(415) 722-4563
icooney@matinasbiopharma.com
FAQ
What events is Matinas BioPharma (MTNB) participating in September 2020?
What time will Matinas BioPharma's presentation be at the LD Micro Virtual Conference?
When is the HC Wainwright 22nd Annual Global Investment Conference?
How can investors arrange meetings with Matinas BioPharma during the conferences?
Where can I find the live webcast of Matinas BioPharma's presentations?
